AR068140A1 - Amidas heterociclicas y metodos de uso de las mismas - Google Patents
Amidas heterociclicas y metodos de uso de las mismasInfo
- Publication number
- AR068140A1 AR068140A1 ARP080103772A ARP080103772A AR068140A1 AR 068140 A1 AR068140 A1 AR 068140A1 AR P080103772 A ARP080103772 A AR P080103772A AR P080103772 A ARP080103772 A AR P080103772A AR 068140 A1 AR068140 A1 AR 068140A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- 6alkyl
- alkoxy
- alkyl
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente se relaciona con compuestos de amida heterocíclica, que son utiles para inhibir la vía Hedgehod, y con su uso para tratar una enfermedad o condicion médica mediada solo por inhibicion de la vía Hedgehod o mediada en parte por inhibicion de la vía Hedgehod. También se divulgan composiciones farmacéuticas que incluyen a estos compuestos, y el uso de estos compuestos en la fabricacion de medicamentos para tratar dichas enfermedades y condiciones médicas en un sujeto. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) en donde ---- representa un enlace simple o un enlace doble; ------ representa un enlace simple, un enlace doble, un enlace triple, o cuando X o Y en un enlace directo ----- representa la ausencia de enlace; R1, R2, R3, y R4 se seleccionan en forma independiente entre sí entre el grupo que consiste en hidrogeno, alcoxi C1-6, alcoxi C1-6-alquiloC1-6, alquilo C1-6, amino C1-6alquilo, cicloalquilo C3-8, ciano, haloC1-6alquilo, halogeno, hidroxi, sulfonilo, sulfuro, y tio, con la condicion de que R2 o R3 es Z; cada W se selecciona en forma independiente entre el grupo que consiste en CR10, NR10, N, O, y S, donde R10 se selecciona entre el grupo que consiste en hidrogeno, alcoxi C1-6, alcoxi C1-6-alquiloC1-6, alcoxicarbonilo C1-6, alquilo C1-6, amidino, amido, amino, arilo, carboxamido, ciano, haloC1-6alquilo, halogeno, heterociclilC1-6alquilo, cicloalquilo C3-6, hidroxi, hidroxiC1-6alquilo, nitro, sulfuro, sulfonamido, y sulfonilo, o dos átomos de W adyacentes pueden tomarse junto con sus sustituyentes R10 para formar un segundo anillo fusionado, en donde el segundo anillo se selecciona entre el grupo que consiste en arilo, cicloalquilo C3-8, un heteroarilo de 5 o 6 miembros, y un heterociclilo de 5 o 6 miembros; q es 0 o 1, donde si q es 0 y dos átomos de W adyacentes tomados junto con sus sustituyentes R10 forman un biciclo seleccionado entre el grupo que consiste en benzimidazolilo, benzoxazolilo, benzotiazolilo, y oxazolopiridilo, entonces al menos un A es N, si q es 1, dos W son N, y das átomos de W adyacentes tomados junto con sus sustituyentes R10 forman un quinoxalinilo, entonces al menos un A es N, y si q es 1 y cada W es CR10, entonces dos átomos de W adyacentes se toman junto con sus sustituyentes R10 para formar un segundo anillo seleccionado entre el grupo que consiste en un heteroarilo de 5 o 6 miembros y un heterociclilo de 5 o 6 miembros; R5 se selecciona entre el grupo que consiste en alquilo, haloC1-6alquilo, y halogeno; R6, R7, R8 y R9 se seleccionan en forma independiente entre sí entre el grupo que consiste en hidrogeno, alquilo C1-6, amino, cicloalquilo C3-8, alcoxi C1-6, ciano, haloC1-6alquilo, halogeno, sulfuro, sulfonilo, y sulfonamido; cuando se unen por un enlace simple, X y Y se seleccionan en forma independiente entre sí entre el grupo que consiste en O, S, SO2, NR11, y CR11R12, o uno de X y Y puede ser un enlace directo, cuando se unen por un enlace doble, X y Y son en forma independiente entre sí CR11, y cuando se unen por un enlace triple, X y Y son cada uno C; cada R11 y R12 se selecciona en forma independiente entre el grupo que consiste en hidrogeno, alcoxi C1-6, aIquilo C1-6, amino, ciano, haloC1-6alquilo, halogeno, y sulfuro; cada A se selecciona entre el grupo que consiste en CR13, CR13R13, NR13, N, O, y S; cada R13 se selecciona entre el grupo que consiste en hidrogeno, alcoxi C1-6, alcoxiamino C1-6, alcoxi C1-6-alquilo C1-6, alcoxicarbonilo C1-6, alquilo C1-6, alquilamino C1-6, amidino, amido, amino, aminoC1-6alquilamino, arilo, ariloxi, carboxamido, cicloalquilo C3-8, cicloalquil C3-8-alcoxi C1-6, ciano, haloC1-6alquilo, halogeno, heterociclilo, heterociclilC1-6alquilo, heterociclilC1-6alcoxi, hidroxi, hidroxiC1-6alquilo, hidroxiC1-6alcoxi, nitro, sulfuro, sulfonamido, y sulfonilo; p es 0 o 1, donde si p es 0, entonces dos átomos de A adyacentes pueden tomarse junto con sus sustituyentes R13 para formar un segundo anillo fusionado, en donde el segundo anillo se selecciona entre e! grupo que consiste en arilo, heteroarilo de 6 miembros y heterociclilo de 6 miembros, y si p es 1 entonces dos átomos de A adyacentes pueden tomarse junto con sus sustituyentes R13 para formar un segundo anillo fusionado, en donde el segundo anillo se selecciona entre el grupo que consiste en arilo, heteroarilo de 5 o 6 miembros y heterociclilo de 5 o 6 miembros; o una sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96936407P | 2007-08-31 | 2007-08-31 | |
US3665808P | 2008-03-14 | 2008-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR068140A1 true AR068140A1 (es) | 2009-11-04 |
Family
ID=39967396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103772A AR068140A1 (es) | 2007-08-31 | 2008-08-29 | Amidas heterociclicas y metodos de uso de las mismas |
Country Status (23)
Country | Link |
---|---|
US (1) | US20100311748A1 (es) |
EP (1) | EP2188255A1 (es) |
JP (1) | JP2010537967A (es) |
KR (1) | KR20100047901A (es) |
CN (1) | CN101835752A (es) |
AR (1) | AR068140A1 (es) |
AU (1) | AU2008291921A1 (es) |
BR (1) | BRPI0816050A2 (es) |
CA (1) | CA2696767A1 (es) |
CL (1) | CL2008002560A1 (es) |
CO (1) | CO6321229A2 (es) |
CR (1) | CR11299A (es) |
DO (1) | DOP2010000067A (es) |
EA (1) | EA201000365A1 (es) |
EC (1) | ECSP10010035A (es) |
MX (1) | MX2010002353A (es) |
NI (1) | NI201000033A (es) |
PE (1) | PE20090641A1 (es) |
SV (1) | SV2010003497A (es) |
TW (1) | TW200918521A (es) |
UY (1) | UY31314A1 (es) |
WO (1) | WO2009027746A1 (es) |
ZA (1) | ZA201001194B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090124651A1 (en) | 2007-08-31 | 2009-05-14 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
WO2009075874A1 (en) * | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
US20090281089A1 (en) * | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
CN102098917B (zh) * | 2008-06-19 | 2016-03-16 | 艾科睿控股公司 | 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物 |
WO2010028192A1 (en) | 2008-09-03 | 2010-03-11 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
KR20120099155A (ko) | 2010-01-07 | 2012-09-06 | 셀렉사겐 세라퓨틱스 인크. | 헤지호그 저해제 |
WO2011085261A1 (en) * | 2010-01-08 | 2011-07-14 | Selexagen Therapeutics, Inc. | Hedgehog inhibitors |
WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
JP5769348B2 (ja) * | 2010-03-22 | 2015-08-26 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | 1−(2−フェノキシメチルヘテロアリール)ピペリジン化合物および1−(2−フェノキシメチルヘテロアリール)ピペラジン化合物 |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
EP3524324A1 (en) | 2011-02-28 | 2019-08-14 | BioMarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
CN106220572B (zh) * | 2011-10-28 | 2019-12-13 | 因西必泰克新有限公司 | 哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法 |
PE20221914A1 (es) | 2011-12-28 | 2022-12-23 | Global Blood Therapeutics Inc | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido |
EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
JP6503338B2 (ja) | 2013-03-15 | 2019-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | Hdac阻害剤 |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
KR101971385B1 (ko) | 2013-03-15 | 2019-04-22 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
AU2015214182B2 (en) | 2014-02-07 | 2020-04-30 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
JOP20180072A1 (ar) | 2014-09-11 | 2019-01-30 | Lilly Co Eli | علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين |
CN104529905B (zh) * | 2014-12-09 | 2017-10-31 | 沈阳药科大学 | N‑3‑苯并咪唑酰双胺类衍生物及其制备方法与应用 |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
JP6796638B2 (ja) | 2015-06-04 | 2020-12-09 | ペレファーム, インク.Pellepharm, Inc. | ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用 |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
KR102628073B1 (ko) | 2017-01-10 | 2024-01-22 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
UY37556A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
WO2018183122A1 (en) * | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
WO2020072377A1 (en) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
CN110759831B (zh) * | 2019-10-16 | 2022-09-27 | 浙江金伯士药业有限公司 | 制备常山酮中间体2-氨基-4-溴-5-氯苯甲酸方法 |
AU2022295990A1 (en) | 2021-06-18 | 2024-01-04 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CA2767153A1 (en) * | 2003-02-20 | 2004-09-02 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
PL1789390T3 (pl) * | 2004-09-02 | 2012-04-30 | Genentech Inc | Pirydylowe inhibitory szlaku sygnałowego hedgehog |
BRPI0617852A2 (pt) * | 2005-10-25 | 2011-08-09 | Shionogi & Co | compostos derivados de aminodi-hidrotiazina assim como composições contendo os mesmos |
-
2008
- 2008-08-28 TW TW097132957A patent/TW200918521A/zh unknown
- 2008-08-29 BR BRPI0816050A patent/BRPI0816050A2/pt not_active IP Right Cessation
- 2008-08-29 AU AU2008291921A patent/AU2008291921A1/en not_active Abandoned
- 2008-08-29 US US12/675,728 patent/US20100311748A1/en not_active Abandoned
- 2008-08-29 EP EP08788726A patent/EP2188255A1/en not_active Withdrawn
- 2008-08-29 CN CN200880112906A patent/CN101835752A/zh active Pending
- 2008-08-29 CA CA2696767A patent/CA2696767A1/en not_active Abandoned
- 2008-08-29 EA EA201000365A patent/EA201000365A1/ru unknown
- 2008-08-29 UY UY31314A patent/UY31314A1/es unknown
- 2008-08-29 KR KR1020107006485A patent/KR20100047901A/ko not_active Application Discontinuation
- 2008-08-29 WO PCT/GB2008/050756 patent/WO2009027746A1/en active Application Filing
- 2008-08-29 AR ARP080103772A patent/AR068140A1/es unknown
- 2008-08-29 CL CL2008002560A patent/CL2008002560A1/es unknown
- 2008-08-29 PE PE2008001466A patent/PE20090641A1/es not_active Application Discontinuation
- 2008-08-29 JP JP2010522457A patent/JP2010537967A/ja active Pending
- 2008-08-29 MX MX2010002353A patent/MX2010002353A/es not_active Application Discontinuation
-
2010
- 2010-02-18 ZA ZA2010/01194A patent/ZA201001194B/en unknown
- 2010-02-26 DO DO2010000067A patent/DOP2010000067A/es unknown
- 2010-02-26 NI NI201000033A patent/NI201000033A/es unknown
- 2010-02-26 CR CR11299A patent/CR11299A/es not_active Application Discontinuation
- 2010-02-26 SV SV2010003497A patent/SV2010003497A/es not_active Application Discontinuation
- 2010-03-01 CO CO10023922A patent/CO6321229A2/es not_active Application Discontinuation
- 2010-03-12 EC EC2010010035A patent/ECSP10010035A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SV2010003497A (es) | 2010-07-06 |
CR11299A (es) | 2010-05-28 |
JP2010537967A (ja) | 2010-12-09 |
KR20100047901A (ko) | 2010-05-10 |
EA201000365A1 (ru) | 2010-10-29 |
PE20090641A1 (es) | 2009-06-26 |
UY31314A1 (es) | 2009-03-31 |
ECSP10010035A (es) | 2010-04-30 |
CN101835752A (zh) | 2010-09-15 |
CO6321229A2 (es) | 2011-09-20 |
US20100311748A1 (en) | 2010-12-09 |
WO2009027746A1 (en) | 2009-03-05 |
CA2696767A1 (en) | 2009-03-05 |
AU2008291921A1 (en) | 2009-03-05 |
EP2188255A1 (en) | 2010-05-26 |
ZA201001194B (en) | 2011-12-28 |
CL2008002560A1 (es) | 2009-07-17 |
BRPI0816050A2 (pt) | 2017-05-02 |
MX2010002353A (es) | 2010-05-03 |
TW200918521A (en) | 2009-05-01 |
NI201000033A (es) | 2010-12-07 |
DOP2010000067A (es) | 2010-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR068140A1 (es) | Amidas heterociclicas y metodos de uso de las mismas | |
CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
AR117264A1 (es) | Esteroides neuroactivos y métodos para su uso | |
PE20170775A1 (es) | Derivados de benzodiazepina citotoxicos | |
AR072936A1 (es) | Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer. | |
PE20191260A1 (es) | Compuestos inhibidores del vih | |
AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
PE20130647A1 (es) | Indoles | |
AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
PE20121526A1 (es) | Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c | |
AR052863A1 (es) | Compuestos de quinolina heteroaromaticos | |
DOP2007000079A (es) | Compuestos fenil amido heterocíclicos condensados | |
AR096246A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
AR035211A1 (es) | Derivados de indolilmaleimida, un proceso para su preparacion, una composicion farmaceutica y una combinacion que los comprenden | |
AR054327A1 (es) | Fenil-metanonas sustituidas por heterociclos, procesos de preparacion y composiciones farmaceuticas que lo contienen | |
AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
UY29457A1 (es) | Compuestos novedosos de derivados de aminosulfonilo | |
AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
PE20161476A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
AR086482A1 (es) | Inhibidores de aldosterona sintasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |